Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer

Yamamoto, Yuka; Nishiyama, Yoshihiro; Monden, Toshihide; Sasakawa, Yasuhiro; Ohkawa, Motoomi; Gotoh, Masashi; Kameyama, Kotaro; Haba, Reiji

doi:10.1007/s00259-005-1878-9

Cited by 57 publications

(42 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is even more considerable evidence The results of the present study are in line with other studies on the predictive value of 18 F-FDG PET in locally advanced NSCLC. Several studies indicated a possible role for PET in assessment of response during or after radiotherapy (19), induction chemotherapy (20)(21)(22), or a combination thereof (8,(23)(24)(25)(26)(27). The earliest study, performed in 1996 by Ichiya et al (19), showed a more prominent decrease in 18 F-FDG uptake in patients with a radiotherapy response on CT compared with those with no change in tumor size on CT.…”

Section: Discussionmentioning

confidence: 99%

“…The residual metabolic rate of glucose after completion of induction chemotherapy proved to be the best prognostic factor. The other 6 studies (8,(23)(24)(25)(26)(27) showed that 18 F-FDG PET was also predictive with respect to therapy outcome of combined modality therapy. Metabolic response proved to be associated with pathologic response (23,24,26,27).…”

Section: Discussionmentioning

confidence: 99%

“…The other 6 studies (8,(23)(24)(25)(26)(27) showed that 18 F-FDG PET was also predictive with respect to therapy outcome of combined modality therapy. Metabolic response proved to be associated with pathologic response (23,24,26,27). A study performed by Mac Manus et al (25) showed a significantly longer median survival for patients with complete metabolic response than for patients with incomplete metabolic response (31 vs. 11 mo).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Geus-Oei¹,

Heijden²,

Visser³

et al. 2007

Journal of Nuclear Medicine

119

100

View full text Add to dashboard Cite

The aim of this prospective study was to evaluate the value of 18 F-FDG PET for the assessment of chemotherapy response in patients with non-small cell lung cancer. Furthermore, part of the objective of this study was to compare 2 methods to quantify changes in glucose metabolism. Methods: In 51 patients, dynamic 18 F-FDG PET was performed before and at 5-8 wk into treatment. Simplified methods to measure glucose metabolism (standardized uptake value [SUV]) and quantitative measures (metabolic rate of glucose [MR Glu ]), derived from Patlak analysis, were evaluated. The overall survival and progression-free survival with respect to MR Glu and SUV were calculated using Kaplan-Meier estimates. Fractional changes in tumor glucose use were stratified by the median value and also the predefined EORTC (European Organization for Research and Treatment of Cancer) metabolic response criteria, and criteria applying cutoff levels similar to those of RECIST (Response Evaluation Criteria in Solid Tumors) were evaluated. Results: When stratifying at the median value of DMR Glu and DSUV, the difference in overall survival (P 5 0.017 for DMR Glu , P 5 0.018 for DSUV) and progressionfree survival (P 5 0.002 for DMR Glu , P 5 0.0009 for DSUV) was highly significant. When applying the predefined criteria for metabolic response, the cutoff levels as also used for size measurement (RECIST) showed significant differences for DSUV between response categories in progression-free survival (P 5 0.0003) as well as overall survival (P 5 0.027). Conclusion: The degree of chemotherapy-induced changes in tumor glucose metabolism as determined by 18 F-FDG PET is highly predictive for patient outcome, stratifying patients into groups with widely differing overall survival and progression-free survival probabilities. The use of 18 F-FDG PET for therapy monitoring seems clinically feasible, because simplified methods to measure tumor glucose use (SUV) are sufficiently reliable and can replace more complex, quantitative measures (MR Glu ) in this patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Geus-Oei¹,

Heijden²,

Visser³

et al. 2007

Journal of Nuclear Medicine

119

100

View full text Add to dashboard Cite

show abstract

“…In the sensitive group, the average change from the pretherapy values was 248.96% 6 12.27% for maximum SUV and 251.63% 6 10.45% for mean SUV. SUV did not significantly differ between the groups at any other points (days [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. On day 0, tumor volume was not significantly different between the control group and the sensitive or insensitive groups.…”

mentioning

confidence: 97%

Changes in ¹⁸F-FDG Uptake Within Minutes After Chemotherapy in a Rabbit VX2 Tumor Model

Song

Liu²,

Huang³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

The purpose of this study was to investigate whether 18 F-FDG PET/CT can be used for in vivo chemosensitivity testing and to determine the optimal time point for observation. Methods: Forty-two rabbits with 84 implanted VX2 squamous cell tumors were randomized into a control group (n 5 10) and a treatment group (n 5 32). 18 F-FDG PET/CT was performed the day before intravenous administration of cisplatin (4 mg/kg) and at 95-100 min (day 0), day 1, day 7, and day 14 afterward. In the control group, 18 F-FDG PET/CT images were acquired at the same time points but without cisplatin administration. Maximum standardized uptake value (SUV) and mean SUV were analyzed. On the basis of tumor volume, we categorized animal tumors into a sensitive group and an insensitive group. If tumor volume doubled by day 7, the tumor was considered insensitive. Results: On day 0, maximum SUV and mean SUV were significantly different between the sensitive group and the insensitive and control groups (P , 0.05 for both). In the sensitive group, the average change from the pretherapy values was 248.96% 6 12.27% for maximum SUV and 251.63% 6 10.45% for mean SUV. SUV did not significantly differ between the groups at any other points (days 1-14). On day 0, tumor volume was not significantly different between the control group and the sensitive or insensitive groups. After cisplatin administration, the size of the VX2 xenograft tumors increased slowly. Tumor necrosis fractions on days 7 and 14 were significantly greater in the sensitive group than in the insensitive or control group. Viable tumor cells on days 7 and 14 were less numerous in the sensitive group than in the insensitive or control group. A significant difference in inflammatory cells was seen between the sensitive and insensitive groups on days 7 and 14 (P , 0.05 for both). No significant differences in inflammatory cells or viable tumor cells were seen between the insensitive and control groups at any time points from before therapy to day 14 (P . 0.05 for all). A slight increase in viable tumor cells and inflammatory cells was seen in the sensitive group on day 14, compared with day 7. Conclusion: When 18 F-FDG was injected as early as 40 min after administration of chemotherapy, PET showed significantly decreased in vivo uptake of the tracer in chemoresponsive tumors. This finding suggests that 18 F-FDG PET may be able to discriminate sensitive from insensitive tumors if the imaging is performed immediately after a test dose of chemotherapy. The optimal observation time and methodology for various chemotherapy-tumor combinations will need to be studied to confirm whether this approach can be generalized.

show abstract

“…PET-CT has a high potential for accuracy in determining T and N status in NSCLC patients receiving induction chemotherapy and/or radiotherapy 25,26 Concerning the evaluation of T status, however, the efficacy of PET-CT is limited in the assessment of T2 and T3 lesions or especially small satellite T4 lesions in the same lobe. 25 In the present study, while the NPV of PET-CT was approximately 87% in detecting ipsilateral nodules in both groups, the PPV remained around 50%.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Diagnostic Performance of Preoperative PET-CT for Patients with and without Neoadjuvant Therapy in Non-Small Cell Lung Cancer: Does Induction Therapy Affect the Preoperative PET-CT Results?.

Gürsoy¹

2013

UHOD

View full text Add to dashboard Cite

PET-CT has been widely used for restaging after induction therapy in patients with non-small cell lung carcinoma. We aimed to assess the role of preoperative PET-CT in patients receiving induction therapy and compare with those without induction therapy. Patients treated with surgery for non-small cell lung carcinoma were included. There were two subgroups according to the presence of preoperative induction therapy. The results of preoperative PET-CT in these two groups were compared. There were 217 patients, 58 in neoadjuvant group and 159 in control (without preoperative induction therapy) group. In N2 lymph nodes, the positive predictive value (PPV) was significantly higher in the neoadjuvant group than in the control group (p=0.01), where the negative predictive value (NPV) (p=0.0001) and accuracy (p=0.03) were significantly lower. In aorticopulmonary lymph nodes, the NPV was significantly higher in the control group (p=0.002). In lower N2 lymph nodes, the PPV was higher (p=0.007) and the NPV was lower (p=0.003) in the neoadjuvant group. In N1 lymph nodes, the specificity was found to be lower in the neoadjuvant group (p=0.01). The sensitivity, PPV and accuracy for mass was lower in the neoadjuvant group (p=0.002, p=0.0003, and p=0.001, respectively).The negative predictive value and accuracy of PET-CT were slightly decreased in patients with non-small cell lung carcinoma received induction therapy before surgical resection. PET-CT appears to be beneficial for the assessment of patients those are planned to be treated surgically for lung cancer whether they have received induction therapy or not.

show abstract

Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer

Abstract: FDG-PET may have the potential to predict response to induction chemoradiotherapy in patients with NSCLC.

Cited by 57 publications

References 14 publications

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Changes in ¹⁸F-FDG Uptake Within Minutes After Chemotherapy in a Rabbit VX2 Tumor Model

Comparison of Diagnostic Performance of Preoperative PET-CT for Patients with and without Neoadjuvant Therapy in Non-Small Cell Lung Cancer: Does Induction Therapy Affect the Preoperative PET-CT Results?.

Contact Info

Product

Resources

About

Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer

Abstract: FDG-PET may have the potential to predict response to induction chemoradiotherapy in patients with NSCLC.

Cited by 57 publications

References 14 publications

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Changes in 18F-FDG Uptake Within Minutes After Chemotherapy in a Rabbit VX2 Tumor Model

Comparison of Diagnostic Performance of Preoperative PET-CT for Patients with and without Neoadjuvant Therapy in Non-Small Cell Lung Cancer: Does Induction Therapy Affect the Preoperative PET-CT Results?.

Contact Info

Product

Resources

About

Changes in ¹⁸F-FDG Uptake Within Minutes After Chemotherapy in a Rabbit VX2 Tumor Model